SPHRF - Stopping Infection: A Missing Link In The Delta Puzzle? Unloved Investment Opportunity In Starpharma

• The delta variant of SARS-CoV-2 is changing the rules of engagement because it is highly infectious and it gets passed on rapidly.
• Scientific discoveries help explain why antivirals are ineffective and why nasal treatment looks powerful. Once the virus gets started in a sensitive individual it is hard to stop.
• Vaccines continue to be the main game, but there is a need for nasal prevention/early treatment options.
• Starpharma has such a product, Viraleze, which has convincing evidence of effectiveness; this might be interesting to investors looking for a risky biotech investment.

For further details see: